Filing Flows › Spero Therapeutics (SPRO) › Q1 2026 › vs Q4 2025
Spero Therapeutics (SPRO) Q1 2026 vs Q4 2025 (quarter over quarter)
Spero Therapeutics's revenue fell $41.0M (-99%) from $41.3M in Q4 2025 to $258K in Q1 2026.
Spero Therapeutics, Q1 2026: revenue $258K (-96% year over year), net loss $7.2M, operating cash flow $15.9M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $258K | $41.3M | −$41.0M | -99% |
| Other income, net | $335K | $376K | −$41K | -11% |
| Net loss | $7.2M | −$31.5M | $38.7M | — |
| Costs & expenses | $7.8M | $41.7M | −$33.9M | -81% |
| Operating costs | $7.8M | $9.9M | −$2.1M | -21% |
| Research & development | $2.9M | $5.6M | −$2.7M | -48% |
| General & admin | $4.9M | $4.3M | $587K | +14% |
| Operating cash sources | $23.1M | −$39.9M | $62.9M | — |
| Share-based compensation | $1.1M | $1.0M | $107K | +11% |
| Working capital & other | $22.0M | −$40.9M | $62.8M | — |
| Net loss absorbed | $7.2M | −$31.5M | $38.7M | — |
| Operating cash flow | $15.9M | −$8.4M | $24.2M | — |
Questions
How much did Spero Therapeutics's revenue grow quarter over quarter in Q1 2026?
Spero Therapeutics's revenue fell $41.0M (-99%) from $41.3M in Q4 2025 to $258K in Q1 2026.